Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | PYCR1 | P32322 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24365508 | 0.78 | TAAR1 (0.56) | TAAR1SLC6A4CHEK1HTR2ACCR5 | |
| SCHEMBL27337210 | 0.77 | CCR5 (0.44) | TAAR1SLC6A4CCR5PYCR1 | |
| Hydrochloric Acid SCHEMBL9871973 | 0.76 | CCR5 (0.43) | TAAR1CCR5PYCR1 | |
| SCHEMBL1239323 | 0.73 | TAAR1 (0.44) | TAAR1SLC6A4CHEK1HTR2A | |
| SCHEMBL29433359 | 0.73 | TAAR1 (0.44) | TAAR1SLC6A4CHEK1HTR2A | |
| SCHEMBL19980301 | 0.72 | CCR5 (0.33) | CCR5PYCR1 | |
| SCHEMBL1555487 | 0.71 | HTR2A (0.63) | TAAR1HTR2A | |
| SCHEMBL9485990 | 0.69 | CCR5 (0.42) | TAAR1CCR5PYCR1 | |
| SCHEMBL8551337 | 0.68 | CYP2A6 (0.59) | TAAR1SLC6A4CHEK1HTR2A | |
| SCHEMBL517473 | 0.68 | SLC6A4 (0.83) | SLC6A4HTR2AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879808-B2 | potent activity against resistant pneumococci; for treating domestic fowl | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2010-08-19 | — | — | US | disclosed |
| EP-2151447-A1 | LINCOMYCIN DERIVATIVES AND ANTIBACTERIAL AGENTS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Meiji Seika Kaisha Ltd. (JP) | 2010-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | LAS1L, LCLAT1, LYPLA1 | TAAR1 4340/4885SLC6A4 4668/4885CHEK1 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.